Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs Abstract We recently showed that active immunisation with the nicotine immunoconjugate IP18-KLH reduces the nicotine-induced increase in dopamine (DA) output in the nucleus accumbens (NAC) and prevents reinstatement of nicotine-seeking behaviour in rats. These effects are mediated by altered distribution of nicotine, resulting in reduced amounts of nicotine reaching the brain, thereby interfering with the rewarding properties of the drug. The present study was designed to explore the effect of immunisation against nicotine on mecamylamine-precipitated nicotine withdrawal as assessed by the reduction in DA output in the NAC in rats. Measuring brain reward thresholds and somatic signs of nicotine withdrawal, the effects of immunisation were also tested during chronic nicotine treatment and after its withdrawal. Finally, we examined the effect of immunisation on challenge injections of nicotine on brain reward thresholds after the increases in somatic signs and reward thresholds associated with nicotine withdrawal had dissipated. The results show that immunisation with IP18-KLH prevented the decrease in DA output in the NAC associated with mecamylamineprecipitated nicotine withdrawal. Moreover, immunisation against nicotine did not precipitate a withdrawal syndrome, as measured by brain reward thresholds and somatic signs, in rats chronically exposed to nicotine. Furthermore, the withdrawal syndrome elicited after cessation of chronic nicotine administration was attenuated in immunised rats compared to that of mock-immunised rats. Finally, the lowering in reward thresholds after nicotine challenge injections was attenuated in both naïve and previously nicotine-exposed immunised rats. In conclusion, the present results show that immunisation with IP18-KLH did not precipitate nicotine withdrawal in rats. Thus, immunisation with IP18-KLH may not elicit nicotine withdrawal in smokers either. Furthermore, since the withdrawal syndrome in rats was attenuated by immunisation, the nicotine withdrawal in smokers should not be worsened but may even be ameliorated during a quit attempt.
Introduction
Tobacco smoking, which is generally accepted to be driven by nicotine dependence, has been estimated to be the major preventable cause of morbidity and premature death in the developed world. Presently available smoking cessation aids have only limited effectiveness and better treatments are needed. Active immunisation against nicotine represents a novel approach in the search for more effective medications in treating nicotine addiction. The mechanism of action for the so-called nicotine vaccines is to generate drug-specific antibodies in the individual. The antibodies bind nicotine, detaining it in plasma, thereby decreasing its distribution to the brain Pentel et al. 2000; de Villiers et al. 2004 ). In addition, nicotine distribution to the brain may also be decreased as a consequence of redirected distribution favouring other tissues than the brain (Satoskar et al. 2003) . We have recently shown that immunisation against nicotine with the nicotine immunoconjugate IP18-KLH prevents the nicotine-induced increase in DA output in the nucleus accumbens (NAC) shell , an effect known to be critically involved in the reinforcing effects of acute nicotine. Furthermore, we have shown that immunisation with IP18-KLH prevents the nicotine-induced reinstatement of nicotine-seeking behaviour following extinguished nicotine self-administration in rats . Thus, our previous results suggest that active immunisation against nicotine may be useful both to prevent the reinforcing effects of acute nicotine and, furthermore, in long-term relapse prevention. We hypothesise that active immunisation with IP18-KLH might also be effective in ameliorating the nicotine withdrawal reaction. Therefore, the present study was initiated to examine the effect of active immunisation with IP18-KLH on chronic nicotine treatment and nicotine withdrawal in the rat.
Nicotine withdrawal may be evoked in humans as well as in different animal species following discontinued chronic or intermittent nicotine administration (Shiffman and Jarvik 1976; Malin et al. 1992; Hildebrand et al. 1997; EppingJordan et al. 1998; Isola et al. 1999) ; the discomfort experienced during this condition is the most frequently reported reason for early relapse (Shiffman 1982) . Thus, ameliorating the withdrawal symptomatology is a main target in smoking cessation treatment. The nicotine withdrawal syndrome is comprised of both affective and 'physical' or somatic components. In humans, the somatic symptoms include bradycardia, gastrointestinal discomfort and increased appetite whereas the affective symptoms primarily include craving for nicotine depressed mood, anxiety, dysphoria, irritability and difficulty concentrating (Hughes et al. 1991; West and Grunberg 1991) . It has been hypothesised that avoidance of the affective symptoms is more important than avoidance of the somatic symptoms in maintaining dependence (Watkins et al. 2000a ). Animal models to study different aspects of nicotine withdrawal have previously been developed. In a rodent model for somatic abstinence signs, symptoms such as abdominal constrictions, facial fasculation, eyeblinks, ptosis, gasps, foot licks, shakes, scratches, yawns and genital grooming are observed (Malin et al. 1992; Hildebrand et al. 1997; Epping-Jordan et al. 1998) . The affective symptoms can be studied in animals using the intracranial self-stimulation (ICSS) procedure. This procedure provides the measure of brain reward thresholds which are thought to reflect brain reward function (Stellar and Stellar 1985; Koob 1992, 1993) . Elevations in thresholds are interpreted as a decrease in the reward value of the stimulation and are seen during withdrawal from different drugs of abuse including nicotine (Epping-Jordan et al. 1998; Harrison et al. 2001) . Previous reports have suggested a dissociation in the mechanisms mediating the reward threshold elevations and the increases in somatic signs during nicotine withdrawal (Watkins et al. 2000b; Harrison et al. 2001) . Thus, while the somatic abstinence signs have both a central and a peripheral component, the affective aspects of nicotine withdrawal are considered to be of central origin only (Stinus et al. 1990; Hildebrand et al. 1997; Watkins et al. 2000b; Kenny and Markou 2001) .
There is substantial evidence showing that the mesolimbic DA system is involved in the reinforcing effects of acute nicotine. Lately, DA has additionally been implicated in nicotine withdrawal. For example, a decrease in DA output in the NAC has been observed after mecamylamineprecipitated nicotine withdrawal (Hildebrand et al. 1999) . Moreover, a change in the neuronal activity of the DA neurons in the ventral tegmental area has been described after the discontinuation of chronic nicotine treatment (Rasmussen and Czachura 1995; Liu and Jin 2004) . Whether the decrease in DA output in the NAC is associated with the somatic, affective or both components of nicotine withdrawal has not been delineated. Therefore, for a more complete understanding of the nicotine withdrawal syndrome, it is important to investigate different aspects of the nicotine withdrawal syndrome. To our knowledge, there is only one study published on the effects of immunisation against nicotine on nicotine withdrawal. In that study, Malin et al. (2001) showed that passive immunisation against nicotine prevented the nicotineinduced alleviation of the nicotine abstinence syndrome.
In the present study, the effects of active immunisation against nicotine on various aspects of nicotine withdrawal were examined. To this end, DA output in the NAC and the duration and magnitude of nicotine withdrawal measured by somatic signs and brain reward thresholds were studied. We also explored whether immunisation with IP18-KLH would precipitate nicotine withdrawal by itself, as reflected in both somatic signs and reward thresholds. Finally, we examined whether immunisation might alter the effects of challenge injections of nicotine on reward thresholds in both saline-and nicotine-exposed animals after nicotine withdrawal had dissipated.
Materials and method
Animals Experiment 1 (see Table 1 ): Male Wistar rats (BK, Sollentuna, Sweden) were housed in groups of four in Makrolon 4 cages, in a temperature-controlled environment under a 12-h light/dark cycle (lights on at 6 a.m.) with free access to food and water. Testing was conducted during the light phase of the light/dark cycle. The study was approved by and conducted according to guidelines of the local animal ethics committee, Stockholms Norra För-söksdjursetiska nämnd. Experiment 2 (see Table 1 ): Male Wistar rats (Charles River, Hollister, CA) were housed in pairs under a 12-h light/dark cycle (lights off at 6 a.m.). Testing was conducted during the dark phase of the light/ dark cycle. Animals had free access to both food and water except during testing. Subjects were treated in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the animal facilities and experimental protocols were in accordance with the Association for the Assessment and Accreditation of Laboratory Animal Care and approved by the Institutional Animal Care and Use Committee (IACUC) of The Scripps Research Institute.
Pump implantation Rats were prepared with 28 days Alzet osmotic mini-pumps (model 2ML4, BK Universal AB, Sollentuna, Sweden or Alza Co., Palo Alto, CA, USA) containing either (-)-nicotine hydrogen tartrate 10.27 mg/ kg/day (3.55 mg/kg/day free base) or saline. Pumps were inserted s.c. on the back of the animal parallel to the spine with the flow-moderator directed posteriorly. In experiment 1: rats weighed 250-300 g at the time of pump implantation. Surgery was performed under pentobarbital anaesthesia (60 mg/kg i.p.). After pump insertion the wound was closed with three to four stitches. In experiment 2: rats weighed between 450-650 g at the time of pump implantation. Rats were anaesthetised with an isoflurane/oxygen vapor mixture (1-1.5%). After pump insertion the wound was closed with 9 mm stainless steel wound clips (Becton Dickinson Primary Care Diagnostics, Sparks, MD), and antibacterial Bacitracin ointment was applied to the incision area. For rats in experiment 2: pumps were surgically removed on day 28 using the above described procedure.
Immunisation protocol Experiment 1 and 2: rats were immunised with 0.1 mg of the nicotine immunoconjugate IP18-KLH, coupled as described previously , in Freund's complete adjuvant on day 7 (FCA, Difco Laboratories, Detroit, MI, USA). Injections were given i.p. in a volume of 0.4 ml. Animals received a booster immunisation on day 21 (14 days after the first immunisation) containing 0.1 mg IP18-KLH in Freund's incomplete adjuvant (FIA, Difco Laboratories, Detroit, MI, USA). Mock-immunised rats were injected in the same manner with Freund's adjuvant alone.
Microdialysis surgery Rats were stereotaxically (David Kopf Instruments) prepared with vertical probes in the NAC under pentobarbital anaesthesia (induction dose 60 mg/kg i.p.). The incisor bar was set to -3.3 and coordinates (in mm) were, AP+1.6, ML+0.7 and DV-8.2 from bregma according to the rat brain atlas of Paxinos and Watson (1986) . The probes were constructed in the laboratory and the active surface of the concentric semipermeable membrane was 2.25 mm in length beginning approximately 1 mm from the tip of the probe. Probes were anchored and fixed to the skull with stainless steel screws and dental cement. After surgery, rats were housed individually until microdialysis experiments were performed approximately 48 h later.
Microdialysis apparatus and procedure Experiments were performed in freely moving rats during the light phase of the daylight cycle. The dialysis probes were perfused with a physiological salt solution (Apoteksbolaget, Sweden) containing 147 mM NaCl, 3.0 mM KCl, 1.3 mM CaCl 2 , 1.0 mM MgCl 2 and 1.0 mM sodium phosphate (pH 7.4) at a rate of 2.5 μl/min by means of a microperfusion pump. The perfusate was collected, loaded directly into a sample loop of the injector and automatically injected onto the column every 15 min. The loading and injecting modes of the injector (Valco Instruments Co) were directed by a computerised system using Turbochrome 4 software (Perkin Elmer). The extracellular concentrations of DA, dihydroxyindolacetic acid (DOPAC), homovanilic acid (HVA) and 5-hydroxyindolacetic acid (5-HIAA) were determined by HPLC with electrochemical detection (HPLC-ED). The mobile phase was delivered at a rate of 0.8 ml/min. Electrochemical detection was accomplished using a coulometric detector with a high sensitivity analytical cell that allowed detection of DA and metabolites by sequential oxidation and reduction of the microdialysis samples. Chromatograms were collected on a two-pen chart recorder as well as stored in the computer through the software. The DA output is expressed as percent of baseline, the mean of the three last values immediately preceding the mecamylamine injection at 0 min.
ICSS surgical implantation of electrodes Rats were anaesthetised with an isoflurane/oxygen vapor mixture (1-1.5%) and mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, Calif., USA). The skull was exposed and cleaned, and four skull screws were inserted, one in each quadrant. A bipolar stainless steel ICSS electrode (model MS303/2 Plastics One, Roanoke, Va., USA; diameter 0.25 mm, length 11 mm) was implanted in the posterior lateral hypothalamus AP-0.5 mm; L±1.7 mm from bregma; DV-8.3 mm from dura; (Pellegrino et al. 1979 ) with the incisor bar elevated 5.0 mm above the interaural line. Half of the animals had electrodes on the right side and the remainder on the left side of the brain to counterbalance any possible brain asymmetries (Glick et al. 1980; Markou and Frank 1987) . The top of the electrode was secured to the skull with screws using dental acrylic cement. Surgeries were conducted under aseptic conditions, and electrodes and skull screws were sterilized prior to implantation. A minimum of seven post-operative recovery days were allowed prior to any training and testing. ICSS procedure The ICSS discrete-trial current-threshold procedure is a modified version Koob 1993, 1992 ) of a procedure initially developed by Kornetsky and coworkers (Kornetsky and Esposito 1979) . Rats were first trained to turn the wheel manipulandum on a fixed ratio 1 schedule of reinforcement. That is, when the rat turned the wheel one quarter of a turn, defined as one response, an electrical reinforcer was delivered. Each subsequent quarter turn also resulted in the delivery of an electrical reinforcer. The electrical reinforcers had a train duration of 500 ms, and consisted of 0.1 ms rectangular cathodal pulses delivered at a frequency of 100 Hz. The current intensity delivered was adjusted individually for each rat. After successful familiarisation with this procedure, defined as two sessions of at least 100 reinforcers in less than 20 minutes, the rats were gradually trained on a discrete-trial, current-threshold procedure. At the start of each trial, rats received a non-contingent electrical stimulus. During the following 7.5 s, the limited hold, if the subject responded by turning the wheel a quarter of a turn they received a second, contingent stimulus identical to the previous non-contingent. During a 2-s period immediately after a positive response, further responses were recorded but had no consequences. If no response occurred during the 7.5-s limited hold period, a negative response was recorded. The inter-trial interval (ITI), which followed the limited hold period, had an average duration of 10 s (ranging from 7.5-12.5 s). The responses that occurred during the ITI were recorded as time-out responses and resulted in a further 12.5-s delay of the onset of the next trial. During training, the duration of the ITI and time-out periods imposed by inappropriate ITI responding were gradually increased until the standard task parameters were reached. The subjects received four alternating series of descending and ascending current intensities starting with a descending series. Within each series, the stimulus intensity was altered by 5-μA steps between each set of trials (three trials per set). The initial stimulus intensity was set at 40 μA above the baseline current-threshold for each animal. A series was terminated after either 15 stimulus decrements (or increments) had occurred, or after the determination of the threshold for the series (see below). Each test session typically lasted for 30 min.
ICSS apparatus

ICSS thresholds
The current-threshold for each descending and ascending series was defined as the stimulus intensity between a successful set of trials (positive responses during two or more of the three trials) and the stimulus intensity for the first set of trials, of two consecutive sets, during which the animal failed to respond positively on two or more of the three trials. Thus, during each session, four current-thresholds were recorded and the mean of these values was taken as the current-threshold for each subject each test session. Baseline thresholds were considered stable when there was less than 10% variation over three to five consecutive days. The thresholds were expressed as a percentage of the mean of the last three to five baseline values before treatment.
Somatic signs Somatic signs were assessed under baseline conditions before the first immunisation, at two timepoints after the first immunisation and once after the second immunisation (see Table 1 ). Somatic signs were also assessed during spontaneous nicotine withdrawal at 18 h, 42 h and 66 h after pump removal. During assessment of signs, rats were placed in a plastic cylindrical container (height 30 cm, diameter 29 cm) in which the rats could move around freely. Each subject was observed for 10 min during which occurrence of the following signs were recorded: body shakes, chews, cheek tremors, escape attempts, eyeblinks, foot licks, gasps, genital licks, head shakes, ptosis, scratches, teeth chattering, writhes and yawns. Multiple successive counts of any sign required a distinct pause between episodes. Ptosis, if present continuously, was only counted once per minute. The sum of the total number of somatic signs per 10−min observation period represents the measure of somatic signs.
Blood sampling Blood was collected from rats in experiment 1 once on day 26-28 after termination of the microdialysis experiment. After an overdose of pentobarbital, approximately 1 ml of blood was drawn directly from the heart, and transferred to heparinised tubes. Samples were centrifuged and the supernatant was stored in nunc tubes in the freezer until analyses. For rats in experiment 2 blood was collected on three occasions, on days 21, 28 and 42, see Table 1 . Tails were massaged in order to increase circulation prior to cutting the very tip of the tail. Approximately 500 μl of blood was collected in eppendorf tubes. Samples were centrifuged and the supernatant stored in the freezer until analyses.
ELISA ELISA was performed on blood collected from rats in experiment 1 and 2. ELISA plates (Labsystems, Stockholm, Sweden) were coated, over night at 8°C or for 1 h at 37°C, with 10 μg/ml of an IP18-BSA (bovine serum albumin) conjugate. ELISA plates were washed and subsequently seven dilutions of each serum were added to the plates (dilutions were 1:25, 1:125, 1:625, 1:3,125, 1:15,625, 1:78,125, 1:390,625) that were then incubated in 37°C. The plates were washed again and the secondary antibody, an alkaline phosphatase conjugated goat anti-rat IgG, (Sigma Aldrich) was added and the plates were further incubated at 37°C. The enzyme substarate p-nitrophenyl phosphate (Sigma-Aldrich) was added. This enzyme produces a coloured end-product that can be measured spectro-photometrically at 405 nm. Plates were read spectrophotometrically and titers were determined as the dilution that produced a positive signal, i.e. the concentration for each serum corresponding to the mean absorbance of the seven measures of the control sera plus two standard deviations. The inclusion criteria for immunised rats was set to titers higher than 1:10,000.
Competitive ELISA Competitive ELISA was performed, on blood collected from rats in experiment 2 as the regular ELISA with the modification that only one dilution of serum was used. The serum dilution selected had given 60-80% of the maximum absorption in the regular ELISA. Instead, different dilutions of the competitors (S)-nicotine and (S)-cotinine were tested in concentrations from 1 nM to 10 mM in steps of 10. The competitor concentrations of nicotine and cotinine that produced a 20 % inhibition of the signal i.e. the IC 20 value, was determined for each rat serum. The mean IC 20 values for each group were subsequently used to calculate the cross-reactivity of cotinine compared to nicotine.
Nicotine and cotinine concentration analyses Nicotine and cotinine analyses were performed on the blood taken from rats in experiment 1, at the Bioanalytical Laboratory at Consumer Healthcare, Pfizer, in Helsingborg, Sweden. Nicotine and cotinine and their respective internal standards methylanabasine and N-etylnorcotinine were extracted from serum using a single step liquid-liquid extraction, with toluene/N-butyl alcohol, after addition of 5 M NaOH. Samples were injected onto a HP 5890A gas chromatograph equipped with capillary columns, CP-sil-8 CB 25 m×32 mm id (Chrompack). Nicotine and cotinine were detected by means of a nitrogen sensitive detector giving high selectivity and sensitivity.
Experimental design
Experiment 1: effect of immunisation against nicotine on the DA output in the NAC during mecamylamineprecipitated nicotine withdrawal
Rats were prepared with 28-day osmotic mini-pumps containing nicotine (day 0) and immunised (n=9) or mockimmunised (n=7) on day 7 and 21. Microdialysis membranes were inserted into the NAC on either day 24, 25 or 26. Two days after insertion of the membrane, on either day 26, 27 or 28, the microdialysis experiments were performed. During the experiment, DA output was allowed to stabilise to obtain 3 baseline observations before mecamylamine was injected at time point 0 min. DA output was assessed for 180 min after the injection. Blood samples were taken at the end of the experiment for analyses of antibody titers as well as for nicotine and cotinine concentration determinations.
Experiment 2: effect of immunisation against nicotine on the effects of chronic nicotine treatment and nicotine withdrawal measured by brain reward thresholds and somatic signs
Rats were prepared with self-stimulation electrodes in the lateral posterior part of the hypothalamus and subsequently trained to turn a wheel to receive electrical reinforcing stimuli. Reward thresholds were assessed daily throughout the experiment with the exceptions that no testing was performed on days 1, 3 and 5 after pump implantation. After the establishment of stable baseline thresholds defined as less than 10% variation over five consecutive sessions, rats were prepared with 28-day osmotic minipumps containing either saline or nicotine (day 0). Pumps were subsequently removed on day 28. Saline-and nicotine-exposed rats were immunised or mock-immunised on day 7 and 21. In experiment 2, the treatment groups were saline-exposed mock-immunised (n=7), saline-exposed immunised (n=10), nicotine-exposed mock-immunised (n=9) and nicotine-exposed immunised (n=9). Somatic signs were assessed in five animals from each experimental group. A baseline observation of somatic signs was obtained before the first immunisation on day 6 or 7. Blood samples were taken on day 21 before the second immunisation, on day 28 before removing the pumps and on day 42 for antibody titer and selectivity determinations.
A. Effect of immunisation with IP18-KLH on brain reward thresholds and somatic signs during chronic nicotine exposure The experiment was performed in order to determine whether immunisation with IP18-KLH by itself would precipitate nicotine withdrawal as measured by a shift in brain reward thresholds or somatic signs. Brain reward thresholds were assessed daily from the second day after the first immunisation to the day of pump removal. Somatic signs were assessed on two occasions after the first immunisation on pump days 13-14 and pump days 19-20, and on one occasion after the second immunisation on pump day 27.
B. Effect of immunisation with IP18-KLH on nicotine withdrawal as assessed by brain reward thresholds and somatic signs The experiment was performed to determine whether immunisation with IP18-KLH would attenuate nicotine withdrawal. On day 28, the pumps were removed to induce nicotine withdrawal. Brain reward thresholds were assessed at 18, 42 and 66 h after pump removal, while somatic signs were assessed approximately 30 min after each individual ICSS session.
C. Effect of immunisation with IP18-KLH on the effects of challenge injections of nicotine in nicotine-naïve and previously nicotine-exposed animals on brain reward thresholds The experiment was performed in order to determine whether immunisation with IP18-KLH would attenuate the effects of challenge injections of nicotine on brain reward thresholds in nicotine-naïve and previously nicotine-exposed animals. After the reward thresholds and somatic signs had returned to baseline following nicotine withdrawal in experiment 2B, rats were exposed to two doses of challenge injections of nicotine. Baseline was defined as the mean threshold from the three consecutive sessions/day immediately preceding the first challenge injection; i.e., days 35-37. Half of the groups received nicotine 0.5 mg/kg s.c. on day 38 (i.e. withdrawal day 10) and the remaining half of the subjects on day 40 (withdrawal day 12). A control saline injection was administered the day nicotine was not administered. The procedure was repeated for nicotine 0.25 mg/kg s.c. on days 41 and 42 (i.e. withdrawal day 13 and 14). All injections were administered 10 min before the brain reward threshold assessments. In experiment 2C, the treatment groups were saline-exposed mock-immunised (n=8), saline-exposed immunised (n=11), nicotine-exposed mock-immunised (n=10) and nicotine-exposed immunised (n=10).
Statistical analyses
Experiment 1: the effect of mecamylamine-precipitated nicotine withdrawal on DA output in the NAC was analysed with repeated measures two-way ANOVA as well as by one-way ANOVA analyses with repeated measures followed by Newman-Keuls post-hoc test to determine the effects within the different groups over time. Two-tailed Student's t-tests were used to evaluate potential group differences in antibody titers, basal levels of DA, DOPAC, HVA and 5-HIAA, concentrations of nicotine and cotinine in plasma and mean DA output after mecamylamineprecipitated nicotine withdrawal. Pearson's correlation test was used to determine whether antibody titers and plasma concentrations of nicotine were correlated.
Experiment 2: three-way ANOVAs were used to identify multiple interactions of drug exposure, immunisation and time during chronic drug exposure for analyses of reward thresholds, after discontinued drug exposure for both somatic signs and reward thresholds and also for reward thresholds after challenge injections of nicotine. Repeated measures two-way ANOVAs were used to identify group differences of reward thresholds and somatic signs over time; these were followed by Newman-Keuls post-hoc analyses when appropriate. One-way ANOVAs were used to detect possible differences in basal threshold and values of somatic signs between groups. One-way ANOVAs with repeated measures were used to determine the effects on reward thresholds and somatic signs within the different groups during drug-exposure and after pump removal. Furthermore, one-way ANOVAs with repeated measures followed by Newman-Keuls post-hoc test were used to evaluate the threshold effects of challenge injections of nicotine compared to saline. According to our a-priori hypothesis, two-tailed t-tests were used to analyse the effects on somatic signs and reward thresholds between groups at specific time-points after cessation of nicotine treatment. Antibody titers and IC 20 values for nicotine and cotinine were compared between groups using two-tailed student's t-tests. Pearson's correlation test was used to determine whether somatic signs and thresholds were correlated during spontaneous withdrawal (18 h).
Results are expressed as mean±SEM . The level of significance was set at a P-value less than 0.05. For an overview of the experimental protocol see Table 1 .
Results
Antibody titers and selectivity
In experiment 1, all IP18-KLH immunised rats had titers exceeding the inclusion criteria, 1:10,000, mean titers were 260,000±50,000. Mock-immunised rats had no detectable levels of antibodies against nicotine. In experiment 2, titers were higher than the inclusion criteria, 1:10,000 in all IP18-KLH immunised animals on all three occasions (see Table 1 , data not shown). Mock-immunised rats had no detectable levels of antibodies against nicotine. The t-test showed no significant difference in titers of antibodies against nicotine between rats chronically exposed to saline or nicotine on day 42, mean titers were 354,000±17,000 and 262,000±43,000, respectively (P>0.05). The blood taken on day 42 was also used to evaluate the selectivity of the antibodies for nicotine. IC 20 values were determined for both nicotine and cotinine in immunised saline and nicotine-exposed rats. The antibodies' selectivity for nicotine was set to 100% and the cross-reactivity of cotinine was determined from the IC 20 values of cotinine compared to nicotine, see Table 2 . Unpaired t-test showed no significant difference in IC 20 values for either nicotine or cotinine between saline and nicotine-exposed rats (P>0.05), see Table 2 .
Plasma nicotine and cotinine concentrations
Experiment 1 plasma concentration of nicotine was significantly higher in IP18-KLH immunised (78.5±15.2 ng/ ml) compared to mock-immunised rats (35.4 ±3.5 ng/ml) (P<0.05). Cotinine levels, however, did not differ between IP18-KLH immunised (362±26 ng/ml) and mock-immunised rats (341±13 ng/ml) (P>0.05).
Experiment 1: effect of mecamylamine-precipitated nicotine withdrawal on extracellular DA, DOPAC, HVA and 5-HIAA levels There was no difference in basal levels of DA, DOPAC, 5-HIAA or HVA between nicotine treated rats that were IP18-KLH immunised or mock-immunised (P>0.05). Levels (mean±SEM) expressed as fmol/min for immunised and mock-immunised groups respectively were: DA: 1.80±0.31; 2.02±0.61, DOPAC: 426±65; 398±69, 5-HIAA: 520±46; 525±34, HVA: 877±648; 231±39.
A significant effect of immunisation [F(1,168)=4.97, P<0.05] and time [F(12,168) =6.64, P<0.001] was observed on the DA output between IP18-KLH immunised and mock-immunised rats treated with nicotine for 4 weeks (P<0.05) as shown by two-way ANOVA. However, there was no interaction effect [F(12,168)=0.53, P>0.05]. Oneway ANOVAs were performed on both treatment groups to further analyse the data. A significant decrease in DA output was observed in the mock-immunised group compared to baseline (P<0.05). However, no significant decrease in DA output was observed at any time-point compared to baseline in the IP18-KLH immunised group (P>0.05), see Fig. 1a . According to our a priori hypothesis a t-test of the mean DA output from 0-180 minutes revealed a significant reduction in DA output in the mockimmunised group compared to the IP18-KLH immunised group (P<0.05), see Fig. 1b . As shown by two-way ANOVAs, there were no interaction effects or main effects of immunisation on either DOPAC, 5-HIAA or HVA output but there were significant effects of time for the output of both DOPAC [F(12,156) , closed squares) . The asterisks represent a significant difference between different time-points and the last baseline-point in the mock-immunised group. b Mean DA output following precipitated nicotine withdrawal, the asterisks represent a significant difference between immunised and mock-immunised rats olds between baseline and day 2 to day 28 were observed in either of the nicotine-exposed groups or in the salineexposed immunised groups (P>0.05) as shown by oneway ANOVAs, see Fig. 2 .
Somatic signs A two-way ANOVA with repeated measures was performed showing no significant main treatment (immunisation and drug exposure) or interaction effects, but a significant effect of time [F(3,48) =5.07, P<0.01] during chronic saline or nicotine exposure. Further oneway ANOVA analyses with repeated measures followed by Newman-Keuls post-test revealed no significant effect on the number of somatic signs in any group between baseline assessment (day 6-7) and assessment 1 (day 13-14), assessment 2 (day 19-20) and assessment 3 (day 27), i.e. during chronic saline or nicotine exposure before and after immunisation (P>0.05, data not shown). The results from the four observations were therefore pooled and the number of somatic signs (mean±SEM) were; for salineexposed mock-immunised 6.5±0.6, for saline-exposed immunised 8.2±0.6, for nicotine-exposed mock-immunised 6.4±0.6, for nicotine-exposed immunised 7.7±0.6. There were no significant differences in the mean number of somatic signs for the pooled values between groups (P>0.05) as determined by a one-way ANOVA. The mean of the pooled values were then defined as baseline and set to 100%. These new baselines were used to assess the effects of spontaneous withdrawal on somatic signs, see below.
Experiment 2B Effect of immunisation with IP18-KLH on brain reward thresholds and somatic signs during spontaneous nicotine withdrawal Brain reward thresholds The three-way ANOVA revealed significant main effects of pump exposure [F(1,31) [F(3,27 )=5,34, P<0.01], there was a significant elevation in reward thresholds 18 h after pump removal compared to baseline as shown by Newman-Keuls post-test (P<0.01). In the nicotine-exposed mock-immunised group [F(3,24) = 11.58, P<0.001] there were significant elevations in reward thresholds at 18 h, 42 h and 66 h after pump removal compared to baseline, while in the nicotine-exposed immunised group [F(3,24) = 9.40, P<0.001] thresholds were only elevated at the first assessment time-point i.e., 18 h after withdrawal compared to baseline also shown by Newman-Keuls post-test, see Table 3 . Furthermore, t-tests used according to our a priori hypothesis, revealed significant elevations in thresholds at both 18 h and 42 h after pump removal in the nicotineexposed mock-immunised group compared to the salineexposed mock-immunised group (P<0.05), see Table 3 . Most importantly, there were no differences in thresholds between the saline and nicotine-exposed immunised groups at either 18 h or 42 h (P>0.05).
Somatic signs Because there were no significant differences in somatic signs between the baseline assessment and the three observations during chronic nicotine or saline exposure after immunisation (assessments 1-3) the mean of the four observations for each group was pooled, defined as baseline and set to 100%, see above. Somatic signs after pump removal were then expressed as percent of this baseline value. The three-way ANOVA showed a significant main effect of day [F(3,51) Fig. 3 . As shown with t-test, according to our a priori hypothesis, in mock-immunised rats somatic signs were significantly higher in animals treated with nicotine compared to animals treated with saline (P<0.05) 18 h after pump removal, but again there were no differences between the two groups immunised with IP18-KLH (P>0.05).
Experiment 2C: effect of immunisation against nicotine on brain reward thresholds after challenge nicotine injections in nicotine-naïve and previously nicotine-exposed rats
There were no significant differences in mean absolute baseline threshold values for the various groups as shown by one-way ANOVA the days before the nicotine challenge injections [F(3,35)=0.39, P>0.05]. Average group threshold (mean±SEM) in μA for the different groups were: saline-exposed mock-immunised 108.9±16.6, saline-exposed immunised 92.8±6.88, nicotine-exposed mock-immunised 106.3±12.9 and nicotine-exposed immunised 106.4±11.9. A three-way ANOVA showed significant main effects of pump exposure The results showed that in rats previously exposed to nicotine, challenge injections of nicotine were more effective in Table 3 Reward thresholds at different time-points following withdrawal in immunised and mock-immunised animals chronically exposed to saline or nicotine The asterisks represent a significant difference compared to baseline. The plus sign represent a significant difference compared to mock-immunised saline-exposed group at 18 h withdrawal lowering reward thresholds than in nicotine-naïve rats. Further, the lower nicotine dose used was more effective in lowering the reward threshold across groups compared to the higher dose. There was also an interaction between dose and immunisation showing that in rats immunised with IP18-KLH the effect of challenge nicotine injections on reward thresholds was different compared to the effect in mock-immunised rats. Two-way ANOVA analyses showed no effect of treatment (P>0.05). One-way ANOVAs were performed to further analyse the effect of challenge injections of nicotine versus the control saline injections. The results for the different groups were nicotine-naïve mock-immunised group [F(3,18)=21.13, P>0.0001], nicotine-naïve immunised [F(3,30)=1.249, P>0.05], nicotineexposed mock-immunised [F(3,24)=13.00,P<0.0001] and for the nicotine-exposed immunised group [F(3,27)=10.46, P<0.0001]. Newman-Keuls post-hoc analyses showed that the higher dose of nicotine, 0.5 mg/kg s.c., had no effect on reward thresholds in nicotine-naïve rats irrespective of immunisation (P>0.05), see Fig. 4a . In rats previously exposed to nicotine 0.5 mg/kg nicotine lowered reward thresholds only in the immunised group (P<0.05), see Fig. 4b . The lower dose of nicotine tested, 0.25 mg/kg s.c., was found to lower reward thresholds in nicotine-naïve mock-immunised rats (P<0.01), as well as in immunised and mock-immunised rats previously exposed to nicotine (P<0.001), see Fig. 4a ,b.
Correlation tests
In experiment 1, Pearson's correlation test showed a positive correlation between titers of antibodies against nicotine and plasma concentrations of nicotine, r 2 =0.43, P<0.01.
In experiment 2, there was no correlation between reward thresholds and somatic signs in any of the groups on the first day after pump removal (r 2 ranged between 0.26 and 0.51 in the four treatment groups, P>0.05), nor was there a correlation between the titers of antibodies against nicotine and reward thresholds on the first day after pump removal in the IP18-KLH immunised group including both nicotine and saline-exposed rats (r 2 =0.02, P>0.05), as shown by Pearson's correlation tests.
Discussion
The present study evaluated the effect of active immunisation against nicotine on different withdrawal measures in rats treated chronically with nicotine or saline. The major findings of the present study are that active immunisation with IP18-KLH does not precipitate nicotine withdrawal by itself and that both the spontaneous and precipitated nicotine withdrawal is attenuated after immunisation. In addition, the effects of challenge injections of nicotine on brain reward thresholds are attenuated after immunisation in both nicotine-naïve and previously nicotine-exposed rats.
The results showed that chronic nicotine exposure did not affect the titers of antibodies produced, results which are in line with previous data by Hieda et al. (2000) . There were no differences between nicotine-and saline-treated animals in antibody selectivity towards either nicotine or cotinine, further indicating that the immune-response after immunisation with IP18-KLH is unaffected by concomitant nicotine treatment. Because there were no differences in immune-response between saline-and nicotine-treated rats as measured by amount of antibodies and antibody selectivity, the present results suggest that the administered nicotine did not act to either boost or suppress the immune system in rats immunised against nicotine. Although tobacco smoking has been shown to compromise the immunologic response in humans, and nicotine to produce changes in immunocytes (see McAllister-Sistilli et al. 1998) as well as to suppress the induction of antibodyforming cells in rats (Geng et al. 1995) , smokers are immunised worldwide on a regular basis with different vaccines for different purposes without major setbacks in terms of efficacy. Therefore, neither nicotine administration, as indicated by the present results, nor smoking is expected to significantly interfere with the immunologic response after active immunisation against nicotine. In this study, following a 4-week period of continuous infusion of nicotine (3.55 mg/kg/day, free base), plasma concentrations of nicotine were roughly doubled in immunised rats compared to mock-immunised rats. In a previous study from our laboratory, we have shown a four− to seven−fold increase in plasma nicotine concentrations in IP18-KLH immunised animals compared to mock-immunised rats following acute injections of nicotine (de Villiers et al. 2004) . The dose of nicotine administered appears to affect the differences in plasma nicotine concentrations found in immunised versus mock-immunised rats. Thus, after administration of a high nicotine dose (30 μg/kg i.v., free base) the differences in nicotine concentrations found in plasma between immunised and mock-immunised rats were smaller than after administration of a smaller dose of nicotine (15 μg/kg i.v.). Therefore, the relatively minor differences observed in the present experiment may be due to the large amounts of nicotine administered. These results are consistent with the theoretical notion that a fraction of any amount of nicotine will be bound by antibodies. Moreover, plasma concentrations of nicotine between IP18-KLH immunised and mock-immunised rats seem to differ less with time. Thus, as previously reported, we have noted that 3 min after an acute injection of nicotine (30 μg/ kg i.v.), plasma concentrations of nicotine differed more between immunised and mock-immunised rats compared to 60 min after the same injection (de Villiers et al. 2004 ). In a recent study using another nicotine vaccine, it was shown that 25 min after an acute injection of nicotine (0.1 mg/kg i.v.) there was a 4.5−fold increase in plasma nicotine concentrations in the immunised rats compared to mock-immunised rats (Satoskar et al. 2003) . Interestingly, in the same study, after a 10-week period of continuous nicotine infusion (1 mg/kg/day), there was a 6.9−fold increase in plasma nicotine concentration in the immunised compared to the mock-immunised rats. In fact, a prolonged half-life of nicotine has been observed after immunisation with this vaccine (Satoskar et al. 2003) . Therefore, in using this nicotine vaccine, continuous exposure to nicotine may result in accumulated plasma concentrations of nicotine due to the prolonged half-life. In contrast, our previous results indicate that the half-life of nicotine after immunisation with IP18-KLH does not change, based on the observation that the cotinine concentrations were not altered one hour after nicotine administration. As shown in the present study, cotinine concentrations were still not affected after 26-28 days of continuous nicotine administration. Our present data, therefore, further strengthens the notion that the half-life of nicotine is unaffected by immunisation with IP18-KLH. Changes in the half-life of nicotine after immunisation may be relevant to both the reinforcing effect of nicotine as well as the appearance of nicotine-induced peripheral side-effects.
In the present study, we have shown that after mecamylamine-precipitated nicotine withdrawal, the reduction in DA output observed in mock-immunised rats is reduced in rats immunised with IP18-KLH. These results indicate that active immunisation against nicotine may attenuate the nicotine withdrawal syndrome. Although, it has been suggested that the decrease in DA output in the NAC specifically relates to the affective component of withdrawal (Stinus et al. 1990 ), a recent study suggested that the reduced dopaminergic transmission in the NAC observed during opiate withdrawal is not critical for either the somatic or the affective component of opiate withdrawal (Caillé et al. 2003) . These different conclusions could be related to the fact that different methods were used to evaluate the affective component of withdrawal in the two studies. Thus, it has been suggested that conditioned place preference and assessments of brain reward thresholds measure different aspects of the affective component of withdrawal (Kenny and Markou 2001) . Furthermore, there may be differences between opiate and nicotine withdrawal. Our data, showing that immunisation against nicotine attenuated both DA output in the NAC and elevations in brain reward thresholds during nicotine withdrawal, support the hypothesis that DA is involved in the affective component of nicotine withdrawal, although the evidence provided here is purely correlative.
The present study shows that active immunisation with IP18-KLH does not per se elicit a nicotine withdrawal syndrome in rats continuously exposed to a high dose of nicotine. A slow accumulation of antibodies against nicotine, leading to a slow gradual decrease in pharmacologically active nicotine, i.e. unbound nicotine, may account for the absence of detectable nicotine withdrawal effects. However, after discontinued nicotine administration a withdrawal syndrome appeared in both mockimmunised and IP18-KLH immunised rats, as assessed by both reward thresholds and somatic signs. These results suggest that some nicotine was still able to reach the brain and sustain dependence also in the IP18-KLH immunised rats. The fact that some nicotine was still available to sustain the nicotine dependence is not surprising, given that the amount of nicotine delivered per day via the pumps has been estimated to correspond to the amount of nicotine ingested from smoking 200 cigarettes per day by a human being weighing 70 kg (Benowitz and Jacob 1984) . An increased duration of nicotine treatment has been shown to prolong the duration of the withdrawal reaction, as assessed by elevated brain reward thresholds and somatic signs (Skjei and Markou 2003) . Also, a correlation between total nicotine dose, and the magnitude of elevations in reward thresholds has been observed (Skjei and Markou 2003) . In the present study, the magnitude of the threshold elevations was similar in the two groups treated with nicotine, but a shorter duration of the elevated reward thresholds was observed in rats immunised with IP18-KLH. This pattern of results is similar to the effects seen after pharmacol-ogical reversal of the nicotine withdrawal-induced elevations in brain reward thresholds (Harrison et al. 2001; Markou et al. 2005) . These results indicate that the effect of the nicotine exposure was indeed modulated in the IP18-KLH immunised rats. Surprisingly, we also found a significant threshold elevation in the saline-exposed immunised group of rats. Similarly, it has previously been observed that saline treated rats sometimes display a small elevation in reward threshold on the day after pump implantation (Harrison et al. 2001) or removal (Paterson et al. 2000) , suggested to arise from a possible mild discomfort associated with the surgery the previous day. However, there were no threshold elevations in the mockimmunised saline-exposed rats. Therefore, the threshold elevations seen in immunised rats may not be attributed to the surgery effects. Furthermore, there was a tendency towards an increase in the somatic signs of this group. Although these effects were not correlated, one might speculate that the effects were due to the vaccine. In the present experiment the shift in thresholds after removing the pumps in the saline-exposed immunised rats but not in the mock-immunised animals exposed to saline, may reflect a mere coincidence, since a similar shift is not consistently observed or presumably the effect could be due to a small effect of the vaccine itself. We have observed that preparation of the mock-vaccine composed of only Freund's adjuvant generates an emulsion, which is not as thick as the emulsion generated from mixing IP18-KLH and Freund's adjuvant. Thus, in view of the present results, the difference in formulation may make the formulation with IP18-KLH and Freund's adjuvant more irritant and, hence, the rats more sensitive after the surgical removal of the pumps. Importantly, since Freund's adjuvant is not approved for clinical use and consequently would not be considered in the development of a vaccine for nicotine to be used in humans, this problem would not be an issue in humans.
After cessation of nicotine administration, an increase in somatic signs was observed in both immunised and mockimmunised rats previously exposed to nicotine. However, the effect was clearly less pronounced in the IP18-KLH immunised rats than in the mock-immunised animals. Previously, it has been shown that the number of somatic abstinence signs was proportional to the amount of prior nicotine exposure (Malin et al. 1992; Skjei and Markou 2003) , providing further support for a decreased effect of the nicotine exposure in the immunised animals, as well as for an attenuated nicotine withdrawal syndrome. It should be noted that even less than a third of the dose of nicotine used in the present experiment induces nicotine dependence as assessed by somatic signs after cessation of continuous nicotine administration in rats (Malin et al. 1992) .
In the last part of the present study, challenge injections of nicotine were administered to immunised and mockimmunised rats previously exposed to or naïve to nicotine. The results demonstrate that in nicotine-naïve rats a nicotine dose of 0.25 mg/kg s.c. only lowered the reward thresholds in the mock-immunised rats, showing that immunisation with IP18-KLH blocked the reward facilitating effect of this nicotine dose. These results are in line with our previous results, which demonstrate that active immunisation with IP18-KLH prevents the nicotine induced increase in DA output in the NAC . A higher dose of nicotine (0.5 mg/kg s.c.) was also tested, but this dose had no effect on reward thresholds in nicotine-naïve rats irrespective of immunisation. Interestingly, there was a tendency towards a reward threshold elevation in the mock-immunised group, indicating that this high dose may even be aversive in nicotine-naïve rats. In rats previously exposed to nicotine, the lower dose of nicotine (0.25 mg/kg s.c.) lowered the reward thresholds in both mock-immunised and IP18-KLH immunised rats. Thus, the reward facilitating effect of the lower dose of nicotine used in this experiment was not blocked. However, taking into consideration the route of administration, also this dose of nicotine is quite large and corresponds approximately to the amount of nicotine ingested by smoking 7 cigarettes at the same time. Thus, these results do not exclude clinical efficacy of the vaccine used. The higher dose of nicotine (0.5 mg/kg s.c.) lowered thresholds in the immunised rats but not in the mock-immunised indicating an interactive effect between prior nicotine exposure and reduced nicotine availability due to the vaccine that made that higher nicotine dose have effects similar to those seen with lower nicotine doses in mockimmunised saline-exposed rats. It is possible that nicotinic receptor desensitisation together with a reduced nicotine dose resulted in this effect.
In conclusion, the major findings of the present study are that active immunisation with IP18-KLH prevents the decrease in DA output in the NAC associated with precipitated nicotine withdrawal. Further, we show that immunisation with IP18-KLH by itself does not precipitate either affective or somatic aspects of nicotine withdrawal in rats continuously infused with nicotine during four weeks. Finally, the present study demonstrates that after the discontinuation of nicotine exposure, the withdrawal syndrome is ameliorated in immunised rats. Our data provide support for the notion that active immunisation against nicotine may be useful not only in preventing the acute reinforcing effects of nicotine and in relapse prevention but also during attempts to quit smoking by attenuating both the affective and somatic nicotine withdrawal symptoms.
